G207 is a conditionally replicating derivative of herpes simplex virus type1 (HSV-1) engineered with deletions of both ICP34.5 loci and a lacZ insertion disabling the ICP6 gene. G207 exhibits an efficient oncolytic activity in vitro and in vivo, yet minimal toxicity in normal tissue, and is now in clinical trial for malignant glioma. According to the results of clinical trials, however, although G207 was proved to be safe, the efficacy was not so impressive. Deletion of the ICP34.5 gene coding for virulence made G207 extremely safe, but it markedly reduced the cytotoxicity mediated by HSV-1. To enhance the therapeutic efficacy of G207 without diminishing its safety, we used a defective vector containing Musashi1 promoter/ICP34.5, with G207 as helper virus. P/musashi1 was functional selectively in human glioma cell lines (U87MG, U251, T98G) in this study and dvM345 showed a much higher therapeutic efficacy both in culture and in the in vivo glioma model, than G207 alone, without diminishing its favorable toxicity profile. These results suggest that transcriptional regulation of ICP34.5 by P/musashi1 can be used to target HSV-1 virulence toward gliomas while maintaining the desirable neuroattenuated phenotype.
Introduction
G207, a replication-competent HSV-1 vector, possessing deletions in both copies of the ICP34.5 gene and an insertional mutation in the ICP6 gene, has been proven safe through a number of animal experiments and clinical trials. [1] [2] [3] G207 exhibits an efficient oncolytic activity in a number of in vitro and in vivo studies, yet minimal toxicity in normal tissue. 4, 5 According to the results of clinical trials, however, it seems that the therapeutic efficacy of G207 was insufficient to treat human gliomas in actual clinical settings. Deletion of the ICP34.5 gene, which is also called the neurovirulence factor and functions by enhancing the viral burst size of infected cells, 6, 7 severely attenuated G207 oncolytic activity. In order to enhance therapeutic efficacy, without diminishing its safety, glioma-selective expression of ICP34.5 in oncolytic HSV has been sought.
Musashi1, a neural RNA binding protein, is an evolutionarily well-conserved marker for neural stem cells/progenitor cells. [8] [9] [10] [11] Recently, it has been elucidated that Musashi1 is expressed by a variety of tumors, especially malignant gliomas and could be used as a marker for malignant gliomas. 12, 13 On the other hand, it was shown that the mouse Musashi1 promoter (P/musashi1) is functional also in the fetal human brain, and neural stem cells can be sorted by fluorescenceactivated cell sorting (FACS) on the basis of P/musashi1-driven green fluorescent protein (GFP) expression. 14 Several strategies were reported to render HSV replication selective for tumor cells: (i) deletion or mutation of viral genes needed for replication in postmitotic cells, [15] [16] [17] (ii) deletion of the viral genes responsible for regulating viral progeny production, [18] [19] [20] (iii) use of tumor-specific promoters to regulate the expression of essential viral genes, 21, 22 (iv) altering the receptor specificity of HSV glycoproteins toward tumor rather than normal tissue 23 and so on. Among these, in order to enhance the efficacy of G207, possibly without damaging its safety, we chose the third strategy in this study.
Firstly, we postulated that P/musashi1 would be functional also in malignant gliomas other than in neural progenitor cells, and could thus be used as a tumorspecific promoter to regulate the expression of essential viral genes specifically in malignant gliomas. Then we reasoned that P/musashi1 transcriptional retargeting of g34.5 might provide a means to achieve selective virulence for gliomas while retaining attenuated virulence for normal tissues. In this study, we used a defective vector containing musashi1 promoter/ICP34.5 with G207 as helper virus. We show that this novel system (dvM345), while still exhibiting the requisite degree of safety, has a significantly higher therapeutic efficacy, than G207 alone both in culture and in an in vivo glioma model.
Results

Expression of Musashi1 mRNA in malignant glioma cells
First, we examined the mRNA expression of musahi1 in 10 human-derived tumor cell lines -three malignant gliomas (U87MG, U251, T98), a neuroblastoma (SK-N-SH), a lung cancer (A549), a gastric cancer (TMK-1), a colon cancer (HT29), a bladder cancer (KU19-9), a renal cell carcinoma (A498), and a prostate cancer (DU145) -by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. As shown in Figure 1 , all malignant glioma cells examined were Musashi1 mRNA-positive. SK-N-SH was also positive. In contrast, Musashi1 mRNA was not detected in the other cancer cell lines tested this time.
Transcriptional activity of P/musashi1 in malignant glioma cells
To discover whether Musashi1 promoter functions in a tumor-type specific fashion, and evaluate the function, the transcriptional activity of P/musashi1 was assayed with GFP reporter plasmids in several tumor cell lines, including gliomas where Musashi1 mRNA is expressed or A549 and HT29, where Musashi1 mRNA expression was not detected by RT-PCR analysis. B104 where P/musashi1 is not functional (data not shown) was used as a negative control. In each cell line, the fluorescence level with the CMV promoter (B) was higher than that with P/musashi1 (A). However, the ratio of (A) to (B) among the cell lines was significantly higher in glioma cell lines than in the other cell lines tested ( Figure 2 ).
Patency of pSRaP/musashi1:g34.5 in U87MG in culture To discover and evaluate the effect of g34.5 expression by pSRaP/musashi1:g34.5, pSRaP/musashi1:g34.5 was transfected into U87MG, U251, A549, HT29, and B104.
Mock (phosphate-buffered saline (PBS)) and pHmsi1: GFP were used as controls. After the transfection, G207 was superinfected at a multiplicity of infection (MOI) of approximately 0.01. After 2 days, the resultant viral yield (G207) was counted. The ratio of the viral yield of the cells where pSRaP/musashi1:g34.5 was transfected and the cells where PBS (mock) was transfected was calculated. As expected, the ratio was extremely high in U87MG (8173.61) and in U251 (5179.25), while it was almost 1.0 in A549 (1.1370.15) and in B104 (1.0370.15) where P/musashi1 does not work efficiently, confirming that ICP34.5 was efficiently expressed by P/musashi1 in U87 glioma cell lines. (As a control plasmid, pHmsi1:GFP was also used, and the result was almost the same as mock (PBS).) Data represent means and s.d. of triplicate trials ( Figure 3 ).
In vitro cytopathic efficacy
To analyze the specific cytotoxicity of dvM345, humanderived glioma cell lines in which P/musashi1 works efficiently (U87MG and U251) and the other tumor cell lines in which P/musashi1 does not work efficiently (A549, HT29, and B104) were tested. Cells were infected with dvM345 at an MOI of 0.05, and dvHmsi1:GFP, dvHCRL1, or G207 alone was used as a control. After 18 h postinfection, statistically significant differences were noted between the cytopathic effect of dvM345 and that of control viruses (Po0.05, unpaired t-test), only in glioma cell lines (Figure 4a and b) . On the other hand, in the other tumor cell lines, there was no difference in the cytopathic effect among the viruses used in this study (Figure 4c -e).
Growth characteristics of dvM345 in culture
To see whether the existence of defective vector (dvM345) affects the viral yield of helper virus (G207), single-step growth analysis was performed .   M  U87MG  U251  T98G  SK-N-SH   A549  TMK1  HT29  KU19-9  A498  DU145 200bp-500bp-
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βactin to that with CMV promoter Figure 2 Transcriptional activity of P/musashi1 in several tumor cell lines. The ratio (%) of the hGFP signal intensity with P/musashi1 to that with the CMV promoter is plotted on the vertical axis. It is significantly higher in glioma cell lines than in the other cell lines tested in this study. The data represents the means7s.d. in triplicate.
Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al dvHmsi1:GFP and helper virus (G207) alone were used as negative controls. In U87MG, where P/musashi1 works efficiently, the viral yield of G207 in the dvM345 was significantly higher than that in controls (Po0.05, unpaired t-test) after 12 h postinfection (Figure 5a ), while in A549 where P/musashi1 does not work, no difference was observed (Figure 5b ). We next examined this in primary cultures of mouse cortical astrocytes. Monolayers of passage 3 astrocytes were infected with G207, dvM345, or strain F (wild-type HSV-1) at an MOI of 0.1 and followed for 7 days. At 2 days after infection, isolated plaques were visible on strain F-infected cells, but neither on G207-infected cells nor on dvM345-infected cells. By 7 days after infection, total cytopathic effect was observed on strain F-infected cells, whereas no cytopathic effect was observed on G207-infected and on dvM345-infected cells (data not shown).
Intraneoplastic inoculation in subcutaneous (s.c.) U87MG tumors
Xenograft tumors were established in the subcutaneous (s.c.) tissue of the flank of BALB/c (nu/nu) mice, using the U87MG cell line. Once the tumors had reached approximately 6 mm in diameter, 1.0 Â 10 6 PFU (plaqueforming units) of G207 (group II), dvM345 (group III), or mock extract (group I) was injected intraneoplastically into the flank tumors. From day 6 postinoculation onward, the tumor size of three groups (n ¼ 6/group) diverged ( Figure 6 ). When the experiment was terminated on day 16 because of the large tumor burden (424 mm in diameter) in control animals (group I), the difference of the mean tumor growth ratio between group I and group II was statistically significant (Po0.01, unpaired t-test). More importantly, the difference between group II and group III was also statistically significant (Po0.01). The growth ratio of tumors in group II (G207 treatment) on day 16 was 9.9471.13 (s.e.m.), that in group III (dvM345 treatment) was 1.4270.71, while that in group I (mock extract) was 21.971.37.
All mice, both in the mock infection group and the G207-treated group died because of tumor burden, although mice in the G207-treated group survived longer. In contrast, mice in the dvM345-treated group survived even longer (Po0.05 versus G207; Wilcoxon test).
We also employed 2.0 Â 10 6 PFU in an s.c. tumor model (n ¼ 3) and obtained similar results (dvM345 showed enhanced efficacy compared with G207).
Survival of athymic mice implanted with U87 intracerebral gliomas after treatment with dvM345
In the survival study using nude mice with the intracerebral (i.c.) U87 tumor model, there was a statistically significant prolongation in the survival of mice treated with dvM345 (group III), compared with survival of mice treated with G207 (group II) (Po0.01; Wilcoxon signed rank test) or mock extract (group I) (n ¼ 6/group) (Po0.001; Wilcoxon signed rank test) ( Figure 7 ).
We also employed 1.0 Â 10 6 PFU in an i.c. tumor model (n ¼ 3). All mice treated with G207 died within 32 days after tumor implantation. In contrast, one mouse treated with dvM345 survived 80 days after treatment ( ¼ 90 days after tumor implantation). The other two mice died at day 36 and day 44 after tumor implantation.
Histological analysis of viral transduction by X-gal staining in gliomas
To assess the viral transduction in U87MG i.c. tumors in vivo, mice bearing i.c. U87MG tumors were treated, on day 17 postimplantaion, with 5.0 Â 10 5 PFU of G207 (group II) or dvM345 (group III) and killed on day 5 postinoculation (on day 22 post-tumor implantation). These tumors were stained with X-gal to examine the extent of b-galactosidase expression. Mock-infected tumors showed no b-galactosidase expression ( Figure  8a ). Although tumors in both group II and group III showed b-galactosidase expression, the extent of expression in group III was remarkably larger than that in group II (Figure 8b and c).
Safety evaluation of dvM345 in mice
To evaluate the safety of dvM345, firstly, three BALB/c mice were tested. For i.c. injection, 5.0 Â 10 6 PFU was the highest dose technically obtained in this time. All the mice were still alive 3 months after virus inoculation without any noticeable side effects. The sections of their brains, lungs, livers, and kidneys showed no abnormality other than the scar around the needle tract. Secondly, Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al another 10 BALB/c mice were inoculated at the same dose. Every 7 days, until 28 days after the challenge, we assayed brain homogenates for infectious virus by plaque assay. Infectious virus could never be detected thoughout this schedule by plaque assay with X-gal staining or Giemsa's staining. Lastly, persistence of viral DNA in brain tissue (the inoculated site) 4 weeks after the challenge was detected by PCR amplification, using , and (e) B104. As control viruses, dvHmsi1:GFP, dvHCRL1, and G207 alone were used in (a) and (b). In (c)-(e), dvHmsi1:GFP and G207 alone were used as controls. Between dvM345 and control viruses, a statistically significant difference in the cytotoxic effect was observed after 18 h postinfection both in (a) and (b) (Po0.05; unpaired t-test), while in (c)-(e) there was no significant difference between dvM345 and control viruses. The data plotted are the means7s.d. of triplicate trials.
Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al primers from LacZ, which amplify sequences of 300 bp ( Figure 9 ). However, viral DNA was not detected in other tissues tested during this time (spine, lung, liver, spleen, and kidney) ( Figure 9 ).
Discussion
The malignant glioma, especially glioblastoma multiforme (GBM), is the most common and aggressively invasive form of primary brain tumor in adults. 24 Since GBM tends to extensively infiltrate surrounding normal brain tissue, complete removal of tumor cells is virtually impossible even with the aid of recent improvements in neuroimaging and surgical techniques, necessitating other forms of therapy. Despite major advances in diagnostic procedures, radiation therapy, and chemotherapy, these neoplasms are highly resistant to conventional treatments. [25] [26] [27] Consequently, the prognosis for patients has remained poor in the past two decades, and the majority of patients succumb to the disease within 1 year after diagnosis. 28 The absence of an effective treatment and the extremely poor prognosis of this disease necessitate new therapeutic options such as gene therapy. [29] [30] [31] Since replication-defective vectors have to date failed to achieve a high degree of tumor transduction, replication-competent virus vectors appear to be attractive therapeutic agents for cancer. [32] [33] [34] [35] [36] Since the first description of a virus that was engineered to replicate selectively in dividing cells 14 years ago, 15 the field of viral therapy for cancer has significantly expanded, and at least 10 different viral species have entered clinical trials. 37 A recent development in cancer gene therapy has revolved around the use of genetically engineered, replicationconditional (oncolytic) viruses to deliver cytotoxic genes to tumor cells as well as destroy them directly via lytic infection. 15, [38] [39] [40] [41] The use of replication-conditional herpes Figure 5 Single-step viral growth of dvM345 on the U87MG (a) and A549 (b). The titer of helper virus (G207) was counted every 4 h postinfection. dvHmsi1:GFP and helper virus (G207) alone were used as controls. In U87MG, where P/musashi1 functions efficiently, dvM345 increases the progeny virus production, whereas in A549, where P/musashi1 does not efficiently function, no such effect was seen. Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al simplex virus type1(HSV-1) mutants appears promising for both of the above-mentioned purposes, since its replication within neoplastic cells should allow enhanced anatomic spread of anticancer effects throughout an inoculated tumor mass and augmentation of this effect by delivery of anticancer genes. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Two broad types of replication-conditional HSV mutants in a single gene have been studied to date. The first consists of viral mutants with defects in the function of a viral gene needed for nucleic acid metabolism, such as thymidine kinase, ribonucleotide reductase (RR), or uracyl N-glycosylate. The second consists of viral mutants with defects in the function of the g34.5 gene, which functions as a virulence factor by markedly enhancing the viral burst size of infected cells through suppression of the shutoff of host protein synthesis 6, 7, [43] [44] [45] 49, 50 and by downmodulating MHC class II cell surface expression. 51 The single-mutant strains have certain inherent limitations, including resistance to ganciclovir for mutants in thymidine kinase, the risk of reversion to wild-type by a single recombination event with wild-type virus, and reduced oncolytic efficacy for g34.5 mutants, at least in certain tumor cell lines. In an effort to decrease the risk of wild-type recombination, HSV viruses that are multiply mutated have been developed. These include mutants G207 and MGH1, which possess deletions of both copies of g34.5 and an insertional mutation of RR. 4, 52 These double-mutant strains demonstrate markedly reduced neurovirulence upon direct intracranial injection, retain sensitivity to ganciclovir, and show relatively selective replication in tumor cells compared to normal tissues. Such doublemutant HSV strains retain the defective g34.5 gene, thus demonstrating little virulence toward normal tissues. However, although they clearly demonstrate oncolytic effects against tumor cells, such effects are less than those observed in mutants with intact g34.5 genes. It could be stated that although the deletion of the g34.5 gene made G207 extremely safe, it hampered its therapeutic efficacy to an exact. In fact, according to the clinical results reported so far, the efficacy of HSV strains with defective g34.5 genes in actual clinical settings is not so impressive. 3, 33 Among several strategies to render HSV replication selective to tumor cells, the use of tumor-specific promoters to regulate the expression of essential viral genes is promising. 21, 22 Myb34.5, an HSV mutant with deletion in the gene for RR, carries a version of g34.5 that is under the control of the E2F-responsive cellular B-myb promoter, rather than of its endogenous promoter. 22, 53 Compared with HSV mutants with defective g34.5 Persistence of viral DNA in brain tissue (the inoculated site) 4 weeks after the challenge was detected by PCR amplification, using primers from LacZ, which amplify sequences of 300 bp. However, viral DNA was not detected in other tissues tested in this study (spine, lung, liver, spleen, and kidney).
Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al expression, Myb34.5 showed enhanced oncolytic efficacy against cycling cells in culture, and showed greater antineoplastic activity in mice with diffuse liver metastases by colon carcinoma. 53 If, in the context of G207 treatment, the g34.5 gene were expressed specifically only in glioma cells, the overall therapeutic efficacy should be much higher than when the g34.5 gene is not expressed. As a candidate for glioma selective promoter, we tested and examined P/musashi1.
Musashi1, an evolutionarily conserved neural RNAbinding protein, has recently been shown to be a versatile marker of human glioma cells. 12, 13 Firstly, we checked the mRNA expression of Musashi1 in human glioma cell lines and several of the other cancer cell lines by RT-PCR analysis. We confirmed that Musashi1 mRNA expression is restricted to glioma and neuroblastoma cell lines as far as those tested in this study. This is perfectly consistent with the cases reported earlier.
12,13 Secondly, we investigated the transcriptional activity of P/musashi1, which was originally shown to be functional in neural stem cells of the fetal human brain. 14 We tested the transcriptional activity of P/musashi1 in human glioma cell lines and in several of the other tumor cell lines with a GFP-reporter assay. Our data indicate that the transcriptional activity of P/musashi1 is significantly higher in glioma cell lines than that in the other cancer cell lines investigated. From this result, we postulated that P/musashi1 could be used as a glioma-specific promoter. Thirdly, we constructed a defective virus (dvM345), by reintroducing the g34.5 gene to G207 under transcriptional control of P/musashi1 in the form of the defective vector. In culture, dvM345 exhibited significantly higher cytopathic efficacy in glioma cell lines than G207 alone or control defective vectors. On the other hand, in the other cancer cell lines tested, the difference between dvM345 and G207 alone was not apparent. The result of the single-step viral growth indicates that in U87MG, the higher cytotoxicity of dvM345 comes from the higher progeny virus (G207)-producing ability of dvM345 in glioma cells where P/musashi1 works efficiently. However, this effect was not observed in A549 where P/musashi1 does not work efficiently, again confirming that the enhanced cytotoxicity of dvM345 is probably tumor-type specific. Next, the in vivo therapeutic efficacy of dvM345 was tested using both the s.c. U87 tumor model and the i.c. U87 tumor model in nude mice. In the s.c. tumor model, dvM345 inhibited U87 tumor growth more dramatically than G207 alone. In i.c. U87 tumor model, with a viral PFU as low as 5.0 Â 10 5 , statistically significant increase in survival was seen in the dvM345-treated animals compared with G207-treated group. In both models, the existence of the defective vector (dvM345) enhanced the therapeutic efficacy. Lastly, we examined the safety of dvM345 in mice. Technically, 5.0 Â 10 6 PFU was the highest titer obtained and tested. The i.c. injection of dvM345 in three BALB/c mice caused no noticeable side effects and all the mice survived 90 days after the challenge. Furthermore, we could not detect infectious virus from as early as 7 days to 28 days after the i.c. inoculation in BALB/c mice. At 28 days after the challenge, also, the persistence of viral DNA in brain tissue (the inoculation site) was detected by PCR amplification, using primers for LacZ. However, it was not the case in tissues other than the inoculation site. Combining these results together, it seems unlikely that neurovirulent recombinants, like hrR3, were generated. 1 Considering the nature of Musashi1, which is a neural RNA-binding protein preferentially expressed in primitive, undifferentiated CNS cells, [9] [10] [11] 54 it does not seem likely that its promoter functions in terminally differentiated normal tissue. Our result indicates that P/ musashi1 acts in gliomas in addition to the normal fetal neural progenitor cells. While its activity in terminally differentiated normal tissue was not fully examined, the expression level of Musashi1 is much higher in gliomas than in the surrounding normal brain tissues, 12 indicating the glioma selectivity of the present strategy. However, it should be noted that Musashi1 is also expressed in intestinal epithelial stem cells. 55 Thus, the usage of P/musashi1-driven g34.5 expression in gene therapy might exert some hazardous effects in normal intestinal stem cells and their progenies (normal intestinal mucosa). However, we do not consider that this possibility is likely to be true based on the following reasons. First, the cis elements that are involved in the transcriptional activation of Musashi1 in the intestinal stem cells are not likely to be present within P/musashi1 used in our present and previous studies.
14 Based on previous reports, canonical Wnt signaling is likely to play an important role in the Musashi1 expression in the intestinal stem cells and intestinal adenomas 55 as well as in the maintenance of the intestinal stem cells. 55, 56 However, the trans-activation of P/musashi1-dependent reporter was not induced by the activation of canonical Wnt pathway in the transient transfection assay using the stabilized b-catenin and Tcf-4 expression vectors (S Fukami, T Imai, and Okano, H; unpublished observation). Thus, it is likely that cis elements that are present outside of P/musashi1 are involved in the Musashi1-expression in the intestinal stem cells. 57 In this study, in the context of HSV oncolytic viral therapy, we used a defective vector containing musashi1 promoter/ICP34.5 with G207 as helper virus in order to express ICP34.5 in a glioma-specific fashion and as a result, enhancement of the therapeutic efficacy of G207 was achieved without damaging its safety.
Materials and methods
Cell lines
Human glioma cell lines (U87MG, U251, and T98G), human neuroblastoma cell line SK-N-SH, six humanderived cancer cell lines (lung cancer (A549), gastric cancer (TMK-1), colon cancer (HT29), bladder cancer (KU19-9), renal cell carcinoma (A498), prostate cancer (DU145)), rat neuroblastoma cell line B104, and African green monkey kidney cells (Vero cells) were obtained from the American Type Culture Collection (Manassas, VA, USA). Human glioma cell lines, SK-N-SH, A549, KU19-9, A498, B104, and Vero cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (IFBS). TMK-1 and HT29 were grown in RPMI1640 medium supplemented with 10% IFBS. All cell lines were maintained at 371C in humidified 5% CO 2 with antibiotics (Sigma, St Louis, MO, USA) added to the medium. Passages were usually performed twice a week Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al with 0.25% trypsin-ethylenediaminetetraacetic acid solution (Sigma).
RT-PCR analysis for Musashi1
The expression of Musashi1 mRNA was analyzed with RT-PCR amplification using an RNA panel of 10 humanderived tumor cell lines (U87MG, U251, T98G, SK-N-SH, A549, TMK-1, HT29, KU19-9, A498, and DU145). RNA extraction and RT-PCR were carried out as previously described.
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Transcriptional activity of the Mushashi1 promoter
The transcriptional activity of P/musashi1 in human glioma cell lines (U87MG, U251, and T98G) or other tumor cells (A549, HT29, B104, and Vero cells) was assayed by GFP reporter plasmids, of which the following were used in this study: pm-msi:GFP(truncated), 14 pHCMV:GFP, pHmsi:GFP, and pHCMV.SL amplicon vector. pHCMV.SL amplicon vector was provided by Dr Samuel D Rabkin (Department of Neurosurgery, Georgetown University Medical Center, Washington, DC. USA) and used also as a negative control. pHCMV:GFP was constructed as follows: an hGFP-SV 40 poly(A) fragment was excised by SacII (blunted)/SalI from pm-msi:GFP(truncated) and was inserted at the restriction site for HindIII(blunted)/SalI of pHCMV.SL, as hGFP was driven under the CMV promoter. pHmsi1:GFP was constructed as follows: pHCMV.SL was digested by SpeI and self-ligated, generating pHSL, which lacks the CMV promotor sequence of pHCMV.SL. Then, P/musashi1-hGFP-SV40 poly(A) expression cassette was excised by SalI from pmmsi1:GFP(truncated) and was inserted into pHSL at the restriction site for SalI, as hGFP was driven under P/musashi1. Thus, both pHCMV:GFP and pHmsi1:GFP have the same sequence other than the promoter sequence for hGFP (both have the HSVa and HSVori sequences of pHCMV.SL in common). Cells were plated in glass dishes at a density of 1.0 Â 10 5 cells/ml 1 day prior to transfection of the GFP reporter plasmids. Cells were washed with PBS and the medium was replaced with OPTI-MEM (GIBCO BRL) and transfected with Lipofectamine Plus reagent (Life Technologies, Gaithersburg, MD, USA). At 48 h after transfection, cell were washed twice with PBS and then fixed with 4% paraformaldehyde (Nacalai Tesque, Tokyo, Japan). Transcriptional activity of GFP reporter plasmids was assessed by the intensity of the (hGFP) fluorescence of each well, measured with FluorImager 595 (Molecular Dynamics Japan, Tokyo, Japan) and quantified with ImageQuaNT analysis software (Molecular Dynamics Japan, Tokyo, Japan). The ratio (%) of the hGFP signal intensity with P/musashi1 (A) to that with the CMV promoter (B) was compared among the cell lines.
pSRa P/musashi1:g34.5 amplicon plasmid construction P/musashi1 was excised by HindIII/SacII(blunted) from pm-msi1:GFP(truncated) 14 and was incorporated into a pSRaori4 amplicon plasmid, which was provided by Dr Samuel D Rabkin, at the restriction site for HindIII/BglII, generating pSRaori4:P/musashi1. Plasmid pBGL34. 5, 22 which contains the entire g34.5 coding sequence, was a gift from Peter Pechan (Massachusetts General Hospital, Charlestown, MA, USA). The full-length g34.5 cDNA was excised as an NcoI (blunted)-SacI fragment from pBGL34.5, and was ligated into pKF3 (Takara, Japan) at the restriction site for BamHI (blunted)/SacI, in which the BGHpoly(A) sequence had been incorporated beforehand at the restriction site for SacI/PvuII. The resultant g34.5-BGHpoly(A) sequence was excised by SalI/PvuII, then incorporated into pSRaori4:P/musashi1, generating the amplicon plasmid pSRaP/musashi1:g34.5, which has P/musashi1 upstream and BGHpoly(A) sequence downstream of g34.5 cDNA.
As a preliminary study, to observe the effect of g34.5 expression by pSRaP/musashi1:g34.5, pSRaP/musashi1:g34.5 was transfected into U87MG, U251, A549, HT29, or B104 using Lipofectamine Plus reagent. Mock (PBS) and pHmsi:GFP were used as negative controls, and transfected in exactly the same way as pSRaP/ musashi1:ICP34.5. At 2 days after the transfection, G207 was superinfected at a low MOI. At 48 h after the superinfection, cells were harvested and the resultant viral yield was titrated on Vero cells as described elsewhere. 15 Generation of dvM345, a P/musashi1 promoter-driven g34.5-expressing HSV-1 helper/defective virus vector A pSRa P/musashi1:g34.5 amplicon plasmid was transfected into Vero cells using Lipofectamine Plus reagent. After incubation for about 48 h, the medium was removed; the cells were superinfected with G207 at an MOI of 0.02 and cultured in DMEM with 1% IFBS. Viral stocks were generated according to the method described elsewhere. 44 Titration of G207 helper virus was determined by a plaque-forming assay on Vero cells as described previously. 15 The proportion of defective viral vector within each stock was estimated, based on the cell culture cytotoxicity and the single-step viral growth on U87MG, as described below. The best stock, which showed the highest cytopathic efficacy and viral growth on U87MG, appeared at passage 4. This stock was used thereafter in the in vitro and in vivo experiments. For estimation of defective particle unit (dpu) of the dvM345, we examined the titer (dpu) of control dvHCRL1 (also passage 4) by the method described previously. 59 The titer of defective virus was 6.8 Â 10 7 dpu/ml, and the helper virus (G207) titer of the same stock was 1.0 Â 10 9 PFU/ml. The defective vector:helper virus ratio was 1:14.7.
Cell culture cytotoxicity
We created two control helper/defective viral vectors:dvHmsi1:GFP and dvHCRL1. 59 They were gained by the transfection of pHmsi1:GFP (described above) or pHCRL1 described previously 58, 59 into Vero cells, accompanied by superinfection of G207 as the helper virus, following exactly the same procedure in which dvM345 was made. In this case also, we used the stock gained at passage 4. U87MG, U251, A549, HT29, and B104 cells (1.0 Â 10 6 ) were plated in six-well dishes, 24 h before virus infection. Virus infection was performed in 0.5 ml of PBS supplemented with 1% IFBS for 30 min. Cells were infected with dvM345 at an MOI of 0.05 PFU/cell based on the helper virus (G207) titer, while the controls were mock infected with the extract, prepared from mock-infected cells by the same procedure as that used Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al for the virus inoculum. In the same way, cells were infected with dvHmsi1:GFP or dvHCRL1 at an MOI of 0.05 based on G207 titer. As for glioma cell lines (U87MG and U251), dvHCRL1 was also used as a control virus. The viable cell numbers were determined by the Trypan blue exclusion method every 6 h after infection. All assays were performed in triplicate.
Single-step viral growth
Subconfluent monolayers of U87MG or A549 in six-well dishes were infected at an MOI of 0.05 with dvM345, dvHmsi1:GFP, or helper virus (G207) alone in 0.5 ml of PBS supplemented with 1% IFBS. The count was based on the helper virus (G207) titer. Every 4 h after infection, virus was harvested from the wells and titration of the helper virus (G207) was performed. Plaques were counted and expressed as PFU/ml. Again, experiments were performed in triplicate.
We next examined viral growth in primary cultures of mouse cortical astrocytes. Primary mouse cortical astrocytes were prepared from day 18 Balb/c mouse embryos using a modification 60 of a published procedure. 61 Dissected cerebral hemispheres were dissociated by extrusion through steel mesh and addition of trypsin.
Washed and pelleted cells were cultured in DMEM supplemented with 10% IFBS and antibiotics. Monolayers of passage 3 astrocytes were infected with G207, dvM345, or strain F (wild-type HSV-1) at an MOI of 0.1, and followed for 7 days.
Animal studies
Female athymic BALB/c nude mice (nu/nu) (6-week-old) and female BALB/c mice (four-week-old) purchased from Japan SLC (Shizuoka, Japan) were kept in groups of five or fewer, housed in sterile cages, and had free access to autoclaved food and water. All animal procedures were approved by the Laboratory Animal Center (School of Medicine, Keio University, Tokyo, Japan). Regarding the surgical procedures, each mouse was anesthetized with an intraperitoneal 0.25 ml injection of a solution consisting of 84% bacteriostatic saline, 10% sodium pentobarbital (50 mg/ml; Abbott Laboratories, Chicago, IL, USA), and 6% ethyl alcohol. Mice were visited daily to check their viability status. )day 0, where a is the longer axis and b is the shorter axis. 4, 15, 21 Animals were killed when the tumor diameter was greater than 24 mm. Statistical differences in growth ratio were assessed by using an unpaired t-test.
Model 2: i.c. tumor model and inoculation of the virus
After mice were anesthetized and immobilized in a stereotactic apparatus (D Kopf Instruments, Tujunga, CA, USA). A linear skin incision was made over the bregma and a 1 mm burr hole was drilled in the skull. U87MG cells 2.5 Â 10 5 in 3 ml of serum-free medium were stereotactically injected into the right frontal lobe of nude mice, using a 5 ml Hamilton syringe (Hamilton Company, Reno, NV, USA). After 10 days, mice were randomly divided into three groups (n ¼ 6 per group). Then, 5.0 Â 10 5 PFU of G207 (group II) or dvM345 (group III), or 3 ml mock-infected extract (group I) was inoculated stereotactically at the same coordinates, and survival was followed. Statistical significance of the difference in survival was assessed by the Wilcoxon signed rank test. For pathological studies, mice were treated with 5.0 Â 10 5 PFU of G207 or dvM345, 17 days after implantation, and killed on day 5 post-treatment. After being perfused with 0.5% PFA and 0.5% glutaraldehyde (Nacalai Tesque) in PBS, the brains were removed. The specimens were fixed in 0.5% PFA and 0.5% glutaraldehyde in PBS for 24 h at 41C. The tumors were then placed in substrate solution containing 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal, 1 mg/ml; Takara, Kyoto, Japan), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM magnesium chloride in PBS for 6 h at 371C, washed with PBS, and incubated overnight in cold PBS containing 30% sucrose. After being frozen in OCT compound (Miles, Elkhart, IN, USA) in liquid nitrogen, the brains around the needle tract were sectioned on a cryostat. The sections were mounted onto gelatin-coated glass slides. The slides were washed with PBS, stained with X-gal again overnight, and then counterstained with Neutral Red (Fisher Scientific, Pittsburg, PA, USA).
Model 3: safety evaluation of dvM345 in mice
To evaluate the safety of dvM345, firstly, 5.0 Â 10 6 PFU of dvM345 was injected in the right cerebral hemisphere of three BALB/c mice which were killed 90 days postinoculation. The brains, lungs, livers, and kidneys were removed, fixed and stained in the same manner stated above.
Secondly, the same dose (5.0 Â 10 6 PFU) of dvM345 was injected in the right cerebral hemisphere of another 10 BALB/c mice, and killed on 7, 14, 21, and 28 days postinoculation (two mice per time point) by lethal injection (500 ml of sodium pentobarbital solution).
Brains were removed, quick-frozen and titration of virus was performed following the method described elsewhere.
1 At 28 days postinoculation, furthermore, the remaining two mice were killed and brain tissues around the right frontal cortex (the inoculation site), spines, lungs, livers, spleens, and kidneys were removed. DNA's extracted from these tissues with DNAzol (Invitrogen) following the manufacturer's instruction were used for PCR analysis as described previously. 1 Briefly, the purified DNA was amplified with either a LacZ primer pair that detects uniquely G207 DNA or a mouse b-actin primer pair, which was used as an internal control For the mouse b-actin primer pair, the reactions were 30 cycles at a denaturation temperature of 941C (30 s/cycle), an annealing temperature of 581C (30 s/cycle), and an extension temperature of 721C (1 min/cycle). 62 Their
Musashi1 promoter retargeting of c34.5 to G207 R Kanai et al expected product sizes are 300 bp for LacZ and 550 bp for mouse b-actin. The resultant amplified products were fractionated on a 2% agarose gel, which was then visualized by ethidium bromide staining. The efficiency of cDNA synthesis from each sample was estimated by PCR with the mouse b-actin-specific primers.
